{"pmid":32382072,"title":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.","text":["Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.","The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (M(pro)). Here, the X-ray crystal structure of M(pro) in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 muM) and is a promising lead compound to develop new antiviral treatment for COVID-19.","Nat Struct Mol Biol","Jin, Zhenming","Zhao, Yao","Sun, Yuan","Zhang, Bing","Wang, Haofeng","Wu, Yan","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Du, Xiaoyu","Duan, Yinkai","Yu, Jing","Yang, Xiaobao","Yang, Xiuna","Yang, Kailin","Liu, Xiang","Guddat, Luke W","Xiao, Gengfu","Zhang, Leike","Yang, Haitao","Rao, Zihe","32382072"],"abstract":["The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (M(pro)). Here, the X-ray crystal structure of M(pro) in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic Cys145, whereas its fatty acid tail occupies the hydrophobic S2 subsite. Carmofur inhibits viral replication in cells (EC50 = 24.30 muM) and is a promising lead compound to develop new antiviral treatment for COVID-19."],"journal":"Nat Struct Mol Biol","authors":["Jin, Zhenming","Zhao, Yao","Sun, Yuan","Zhang, Bing","Wang, Haofeng","Wu, Yan","Zhu, Yan","Zhu, Chen","Hu, Tianyu","Du, Xiaoyu","Duan, Yinkai","Yu, Jing","Yang, Xiaobao","Yang, Xiuna","Yang, Kailin","Liu, Xiang","Guddat, Luke W","Xiao, Gengfu","Zhang, Leike","Yang, Haitao","Rao, Zihe"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32382072","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41594-020-0440-6","e_drugs":["1-hexylcarbamoyl-5-fluorouracil"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666419683280027650,"score":9.490897,"similar":[{"pmid":32321856,"pmcid":"PMC7179937","title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.","text":["Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.","SARS-CoV-2 is the etiological agent responsible for the global COVID-19 outbreak. The main protease (M(pro)) of SARS-CoV-2 is a key enzyme that plays a pivotal role in mediating viral replication and transcription. We designed and synthesized two lead compounds (11a and 11b) targeting M(pro) Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. The X-ray crystal structures of SARS-CoV-2 M(pro) in complex with 11a or 11b, both determined at 1.5 A resolution, showed that the aldehyde groups of 11a and 11b are covalently bound to Cys145 of M(pro) Both compounds showed good PK properties in vivo, and 11a also exhibited low toxicity, suggesting that these compounds are promising drug candidates.","Science","Dai, Wenhao","Zhang, Bing","Su, Haixia","Li, Jian","Zhao, Yao","Xie, Xiong","Jin, Zhenming","Liu, Fengjiang","Li, Chunpu","Li, You","Bai, Fang","Wang, Haofeng","Cheng, Xi","Cen, Xiaobo","Hu, Shulei","Yang, Xiuna","Wang, Jiang","Liu, Xiang","Xiao, Gengfu","Jiang, Hualiang","Rao, Zihe","Zhang, Lei-Ke","Xu, Yechun","Yang, Haitao","Liu, Hong","32321856"],"abstract":["SARS-CoV-2 is the etiological agent responsible for the global COVID-19 outbreak. The main protease (M(pro)) of SARS-CoV-2 is a key enzyme that plays a pivotal role in mediating viral replication and transcription. We designed and synthesized two lead compounds (11a and 11b) targeting M(pro) Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity. The X-ray crystal structures of SARS-CoV-2 M(pro) in complex with 11a or 11b, both determined at 1.5 A resolution, showed that the aldehyde groups of 11a and 11b are covalently bound to Cys145 of M(pro) Both compounds showed good PK properties in vivo, and 11a also exhibited low toxicity, suggesting that these compounds are promising drug candidates."],"journal":"Science","authors":["Dai, Wenhao","Zhang, Bing","Su, Haixia","Li, Jian","Zhao, Yao","Xie, Xiong","Jin, Zhenming","Liu, Fengjiang","Li, Chunpu","Li, You","Bai, Fang","Wang, Haofeng","Cheng, Xi","Cen, Xiaobo","Hu, Shulei","Yang, Xiuna","Wang, Jiang","Liu, Xiang","Xiao, Gengfu","Jiang, Hualiang","Rao, Zihe","Zhang, Lei-Ke","Xu, Yechun","Yang, Haitao","Liu, Hong"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32321856","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1126/science.abb4489","locations":["vivo"],"e_drugs":["Aldehydes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493851533312,"score":416.6039},{"pmid":32364011,"title":"FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication.","text":["FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication.","Emergent novel SARS-CoV-2 is responsible for the current pandemic outbreak of severe acute respiratory syndrome with high mortality among the symptomatic population worldwide. Given the absence of a current vaccine or specific antiviral treatment, it is urgent to search for FDA-approved drugs that can potentially inhibit essential viral enzymes. The inhibition of 3CL(pro) has potential medical application, due to the fact that it is required for processing of the first translated replicase polyproteins into a series of native proteins, which are essential for viral replication in the host cell. We employed an in silico approach to test if disulfiram, as well as its metabolites, and captopril could be used as potential antiviral drugs against COVID-19. We provide data on the potential covalent interaction of disulfiram and its metabolites with the substrate binding subsite of 3CL(pro) and propose a possible mechanism for the irreversible protease inactivation thought the reaction of the aforementioned compounds with the Cys145. Although, captopril is shown to be a potential ligand of 3CL(pro), it is not recommended anti-COVID-19 therapy, due to the fact that it can induce the expression of the viral cellular receptor such as, angiotensin-converting enzyme ACE-2, and thus, making the patient potentially more susceptible to infection. On the other hand, disulfiram, an alcoholism-averting drug, has been previously proposed as an antimicrobial and anti-SARS and MERS agent, safe to use even at higher doses with low side effects, it is recommended to be tested for control of SARS-CoV-2 infection.","J Biomol Struct Dyn","Lobo-Galo, Naun","Terrazas-Lopez, Manuel","Martinez-Martinez, Alejandro","Diaz-Sanchez, Angel Gabriel","32364011"],"abstract":["Emergent novel SARS-CoV-2 is responsible for the current pandemic outbreak of severe acute respiratory syndrome with high mortality among the symptomatic population worldwide. Given the absence of a current vaccine or specific antiviral treatment, it is urgent to search for FDA-approved drugs that can potentially inhibit essential viral enzymes. The inhibition of 3CL(pro) has potential medical application, due to the fact that it is required for processing of the first translated replicase polyproteins into a series of native proteins, which are essential for viral replication in the host cell. We employed an in silico approach to test if disulfiram, as well as its metabolites, and captopril could be used as potential antiviral drugs against COVID-19. We provide data on the potential covalent interaction of disulfiram and its metabolites with the substrate binding subsite of 3CL(pro) and propose a possible mechanism for the irreversible protease inactivation thought the reaction of the aforementioned compounds with the Cys145. Although, captopril is shown to be a potential ligand of 3CL(pro), it is not recommended anti-COVID-19 therapy, due to the fact that it can induce the expression of the viral cellular receptor such as, angiotensin-converting enzyme ACE-2, and thus, making the patient potentially more susceptible to infection. On the other hand, disulfiram, an alcoholism-averting drug, has been previously proposed as an antimicrobial and anti-SARS and MERS agent, safe to use even at higher doses with low side effects, it is recommended to be tested for control of SARS-CoV-2 infection."],"journal":"J Biomol Struct Dyn","authors":["Lobo-Galo, Naun","Terrazas-Lopez, Manuel","Martinez-Martinez, Alejandro","Diaz-Sanchez, Angel Gabriel"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32364011","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/07391102.2020.1764393","keywords":["3cl main protease","covid-19","sars-cov-2","disulfiram","thiol-reacting drugs"],"locations":["thiol"],"e_drugs":["Captopril","Disulfiram","Sulfhydryl Compounds"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496018939908,"score":295.57968},{"pmid":32272481,"title":"Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","text":["Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available.","Nature","Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao","32272481"],"abstract":["A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available."],"journal":"Nature","authors":["Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272481","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41586-020-2223-y","e_drugs":["ebselen"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491833024514,"score":279.77313},{"pmid":32198291,"pmcid":"PMC7164518","title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors.","text":["Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (M(pro), also called 3CL(pro)) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 M(pro) and its complex with an alpha-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 M(pro) The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.","Science","Zhang, Linlin","Lin, Daizong","Sun, Xinyuanyuan","Curth, Ute","Drosten, Christian","Sauerhering, Lucie","Becker, Stephan","Rox, Katharina","Hilgenfeld, Rolf","32198291"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency. An attractive drug target among coronaviruses is the main protease (M(pro), also called 3CL(pro)) because of its essential role in processing the polyproteins that are translated from the viral RNA. We report the x-ray structures of the unliganded SARS-CoV-2 M(pro) and its complex with an alpha-ketoamide inhibitor. This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compound in plasma. On the basis of the unliganded structure, we developed the lead compound into a potent inhibitor of the SARS-CoV-2 M(pro) The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route."],"journal":"Science","authors":["Zhang, Linlin","Lin, Daizong","Sun, Xinyuanyuan","Curth, Ute","Drosten, Christian","Sauerhering, Lucie","Becker, Stephan","Rox, Katharina","Hilgenfeld, Rolf"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32198291","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1126/science.abb3405","e_drugs":["Pyridones","Amides"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490109165568,"score":273.88226},{"pmid":32313296,"pmcid":"PMC7165110","title":"Identification of Potential Binders of the Main Protease 3CL(pro) of the COVID-19 via Structure-Based Ligand Design and Molecular Modeling.","text":["Identification of Potential Binders of the Main Protease 3CL(pro) of the COVID-19 via Structure-Based Ligand Design and Molecular Modeling.","We have applied a computational strategy, using a combination of virtual screening, docking and molecular dynamics techniques, aimed at identifying possible lead compounds for the non-covalent inhibition of the main protease 3CL(pro) of the SARS-CoV2 Coronavirus. Based on the X-ray structure (PDB code: 6LU7), ligands were generated using a multimodal structure-based design and then docked to the monomer in the active state. Docking calculations show that ligand-binding is strikingly similar in SARS-CoV and SARS-CoV2 main proteases. The most potent docked ligands are found to share a common binding pattern with aromatic moieties connected by rotatable bonds in a pseudo-linear arrangement.","Chem Phys Lett","Macchiagodena, Marina","Pagliai, Marco","Procacci, Piero","32313296"],"abstract":["We have applied a computational strategy, using a combination of virtual screening, docking and molecular dynamics techniques, aimed at identifying possible lead compounds for the non-covalent inhibition of the main protease 3CL(pro) of the SARS-CoV2 Coronavirus. Based on the X-ray structure (PDB code: 6LU7), ligands were generated using a multimodal structure-based design and then docked to the monomer in the active state. Docking calculations show that ligand-binding is strikingly similar in SARS-CoV and SARS-CoV2 main proteases. The most potent docked ligands are found to share a common binding pattern with aromatic moieties connected by rotatable bonds in a pseudo-linear arrangement."],"journal":"Chem Phys Lett","authors":["Macchiagodena, Marina","Pagliai, Marco","Procacci, Piero"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313296","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.cplett.2020.137489","keywords":["3cl-pro","3cl-pro inhibitor","binding affinity","covid-19","coronavirus","coronavirus main protease","molecular docking","molecular dynamics","sars-cov2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493564223489,"score":252.43623}]}